Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real Life Experience of DAAs in HCV Decompensated Cirrhosis
NCT03547895Completed
- Sponsor
- Zagazig University
- Start
- Jun 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
Open-label trial of sofosbuvir and daclatasvir in hepatitis C (HCV) and decompensated cirrhosis (2 arms), sponsored by Zagazig University. Primary endpoint: Sustained Virological Response. Started Jun 2015; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)decompensated cirrhosis
Beyond the preview
Go deeper on NCT03547895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547895.